Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

The Alabama Poison Information Center has seen an increase in calls relating to children accidentally exposing themselves to ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...

Until now, the drugs have only been available from specialist NHS clinics or private pharmacies, costing around £150 to £200 ...

Patients using Eli Lilly’s Mounjaro are being reminded that the KwikPen injection devices should be discarded after four doses Residual liquid leftover after patients have injected their fourth dose ...

Health insurers will not be covering the cost of a new obesity medication coming on to the market in Ireland. Mounjaro, a ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

At the same time, we are continuing to identify opportunities within our core portfolio that bolster our leadership position in insulin injection ... to co-package our pen needles with potential ...

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from hundreds of millions of patients. The drugmaker's ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...